Phase I and Pharmacokinetic Trial of Gemcitabine in Patients With Hepatic or Renal Dysfunction: Cancer and Leukemia Group B 9565
Authors:
- Alan P. VenookAVAlan P. Venook
- Merrill J. EgorinMEMerrill J. Egorin
- Gary L. RosnerGRGary L. Rosner
- Donna HollisDHDonna Hollis
- Sridhar ManiSMSridhar Mani
- Michael HawkinsMHMichael Hawkins
- John ByrdJBJohn Byrd
- Raymond HohlRHRaymond Hohl
- Daniel BudmanDBDaniel Budman
- Neal J. MeropolNMNeal J. Meropol
- Mark J. RatainMRMark J. Ratain
- 14 July 2000
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 18 (14) , 2780-2787
Abstract
PURPOSE: To ascertain if hepatic or renal dysfunction leads to increased toxicity at a given dose of gemcitabine and to characterize the pharmacokinetics of gemcitabine and its major metabolite in patients with such dysfunction.PATIENTS AND METHODS: Adults with tumors appropriate for gemcitabine therapy and who had abnormal liver or renal function tests were eligible. Patients were assigned to one of three treatment cohorts: I—AST level less than or equal to two times normal and bilirubin level less than 1.6 mg/dL; II—bilirubin level 1.6 to 7.0 mg/dL; and III—creatinine level 1.6 to 5.0 mg/dL with normal liver function. Doses were explored in at least three patients within each cohort. Gemcitabine and its metabolite were to be measured in the blood in all patients.RESULTS: Forty patients were assessable for toxicity. Transient transaminase elevations were observed in many patients but were not dose limiting. Patients with AST elevations tolerated gemcitabine without increased toxicity, but patients with elevated bilirubin levels had significant deterioration in liver function after gemcitabine therapy. Patients with elevated creatinine levels had significant toxicity even at reduced doses of gemcitabine, including two instances of severe skin toxicity. There were no apparent pharmacokinetic differences among the three groups or compared with historical controls.CONCLUSION: If gemcitabine is used for patients with elevations in AST level, no dose reduction is necessary. Patients with elevated bilirubin levels have an increased risk of hepatic toxicity, and a dose reduction is recommended. Patients with elevated creatinine levels seem to have increased sensitivity to gemcitabine, but the data are not adequate to support a specific dosing recommendation.Keywords
This publication has 16 references indexed in Scilit:
- Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer.Journal of Clinical Oncology, 1997
- Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer.Journal of Clinical Oncology, 1997
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.Journal of Clinical Oncology, 1997
- Gemcitabine in patients with advanced malignant melanoma or gastric cancer: Phase II studies of the EORTC Early Clinical Trials GroupAnnals of Oncology, 1994
- Analytical Methods Validation: Bioavailability, Bioequivalence, and Pharmacokinetic StudiesJournal of Pharmaceutical Sciences, 1992
- A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.Journal of Clinical Oncology, 1991
- Changes in the clearance of total and unbound etoposide in patients with liver dysfunction.Journal of Clinical Oncology, 1990
- Carboplatin dosage: prospective evaluation of a simple formula based on renal function.Journal of Clinical Oncology, 1989
- A program package for simulation and parameter estimation in pharmacokinetic systemsComputer Programs in Biomedicine, 1979
- A new look at the statistical model identificationIEEE Transactions on Automatic Control, 1974